Very potent topical corticosteroid
Pregnancy: Avoid unless absolutely necessary. Significant risk of systemic absorption.
Clobetasol Propionate
Brand names: Dermovate, Clarelux
Adult dose
Dose: Apply thinly once or twice daily for up to 4 weeks
Route: Topical (cream, ointment, or scalp foam)
Frequency: Once or twice daily
Max: 50 g/week (body); never exceed
0.05% (very potent — highest potency class). Used for severe psoriasis (non-facial), severe eczema, lichen planus, discoid lupus. Max 4 weeks continuous use then step down. Face and flexures: AVOID. Annual cumulative dose maximum 50 g.
Paediatric dose
Route: Topical
Frequency: Once daily
Max: Avoid in children <1 year; use only under specialist guidance in children
Use only under specialist supervision in children. Very high systemic absorption risk in children. Rarely justified in paediatric practice — prefer lower potency. Annual cumulative dose much lower.
Dose adjustments
Renal
No systemic adjustment for topical use.
Hepatic
No systemic adjustment for topical use.
Clinical pearls
- Reserve for severe, treatment-resistant conditions only
- Max 4 weeks then review — step down to less potent steroid
- DO NOT use on face, groin, axillae — very high absorption
- Scalp foam (Clarelux) useful for scalp psoriasis — less systemic absorption than other formulations
- Annual cumulative limit: 50 g total per year to prevent systemic effects
Contraindications
- All contraindications of topical steroids apply
- Face, flexures, or large body surface areas
- Children <1 year
Side effects
- All side effects of potent steroids (more severe due to high potency)
- Significant HPA axis suppression with excessive use
- Skin atrophy, striae (irreversible)
- Cushing's syndrome (systemic absorption with misuse)
Interactions
- Occlusive dressings significantly increase systemic absorption
Monitoring
- Skin integrity
- Body weight
- Blood glucose
- Signs of adrenal suppression (prolonged large-area use)
Reference: BNFc; BNF; BAD Psoriasis Guidelines; BAD Lichen Planus Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD